Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Benefits From Upper Airway Surgery For Sleep Apnea Found To Equal CPAP
Adults who struggle with CPAP treatment for obstructive sleep apnea (OSA) should be considered candidates for reconstructive surgery on the upper airway, because it holds the same quality-of-life (QOL) benefits but with more permanence. This thesis is in new research published in the August 2009 edition of Otolaryngology-Head and Neck Surgery.
generic viagra online
Dr. Corry Installed As President Of American Veterinary Medical Association
Dr. James Cook officially handed over the title of American Veterinary Medical Association (AVMA) president to Dr. Larry Corry today at the 2009 AVMA Convention President"s Installation Luncheon in Seattle. Dr. Corry, a small-animal practitioner from Buford, Ga., becomes the 129th president of the AVMA. Purchase zoloft to treat depression.
News of the day
Researchers Find First Potential Pathogenic Mutation For Restless Legs Syndrome
An international team of researchers led by scientists at the Mayo Clinic campus in Florida have found what they believe is the first mutated gene linked to restless legs syndrome, a common neurologic disorder.
Medical Devices

FDA Approves Multaq To Treat Heart Rhythm Disorder

The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat. Multaq may cause critical adverse reactions, including death, in patients with recent severe heart failure. The drug"s label will contain a boxed warning, the FDA"s strongest warning, cautioning that the drug should not be used in severe heart failure patients. "Multaq represents a therapeutic innovation for treatment of the heart rhythm disorder of atrial fibrillation," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA"s Center for Drug Evaluation and Research. In a multinational clinical trial with more than 4,600 patients, Multaq reduced cardiovascular hospitalization or death from any cause by 24 percent, when compared with an inactive pill (placebo). Most of that effect represents reduced hospitalizations, especially hospitalizations related to atrial fibrillation. Atrial fibrillation and atrial flutter cause the heart to beat abnormally fast and sometimes prevent blood from being properly pumped out of the heart. The most common adverse reactions reported by patients in clinical trials were diarrhea, nausea, vomiting, fatigue and loss of strength. Multaq is manufactured by Paris-based sanofi-aventis. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009